不同剂量阿托伐他汀对冠脉介入术后血脂, 脂联素和炎性因子的影响研究
张博雅 - 中国实验诊断学, 2014 - cqvip.com
目的: 研究不同剂量的阿托伐他汀对冠脉介入术(PCI) 后患者血脂, 脂联素和炎性因子的影响.
方法选择行PCI 治疗的急性冠脉综合征患者126 例, 随机平均分为三组: A 组患者(42 例) …
方法选择行PCI 治疗的急性冠脉综合征患者126 例, 随机平均分为三组: A 组患者(42 例) …
Complementary, alternative, and putative nontroponin biomarkers of acute coronary syndrome: new resources for future risk assessment calculators
RW Millard, M Tranter - Revista Española de Cardiología (English Edition), 2014 - Elsevier
Biomarkers, other than cardiac troponin, with potential sensitivity and selectivity that provide
diagnostic and prognostic insights into the tissue–specific injury processes underlying acute …
diagnostic and prognostic insights into the tissue–specific injury processes underlying acute …
Biomarcadores no troponínicos, complementarios, alternativos y presuntos, para el síndrome coronario agudo: nuevos recursos para los futuros instrumentos de …
RW Millard, M Tranter - Revista Española de Cardiología, 2014 - Elsevier
En este artículo se revisan los biomarcadores no troponínicos con posibles sensibilidad y
selectividad, que aportan una perspectiva diagnóstica en el síndrome coronario agudo, y su …
selectividad, que aportan una perspectiva diagnóstica en el síndrome coronario agudo, y su …
The interplay between features of plaque vulnerability and hemodynamic relevance of coronary artery stenoses
M Sezer, E Aslanger, O Cakir, A Atici, I Sezer, A Ozcan… - Cardiology, 2021 - karger.com
Fractional flow reserve (FFR) may not be immune from hemodynamic perturbations caused
by both vessel and lesion related factors. The aim of this study was to investigate the impact …
by both vessel and lesion related factors. The aim of this study was to investigate the impact …
氯吡格雷对非ST 段抬高冠脉综合征患者炎症因子及预后的影响
夏晓芬， 李小英， 赵红娟 - 中国临床药理学杂志, 2014 - cqvip.com
目的评价氯吡格雷对非ST 段抬高冠脉综合征(NSTEACS) 患者炎症因子及预后的影响.
方法将我院收治的120 例NSTEACS 患者随机分为氯吡格雷联合阿司匹林组(观察组) …
方法将我院收治的120 例NSTEACS 患者随机分为氯吡格雷联合阿司匹林组(观察组) …
[PDF][PDF] Effect of Phase 2 cardiac rehabilitation program on high-sensitivity C-reactive protein levels in post-percutaneous coronary intervention patients
AM El Missiri, MA Taher - J Cardiovasc Res 5: 1. doi: http://dx. doi …, 2016 - researchgate.net
Objective: To assess the effects of phase 2 cardiac rehabilitation program on hs-CRP levels
in patients revascularized by percutaneous coronary intervention (PCI). Methods: This study …
in patients revascularized by percutaneous coronary intervention (PCI). Methods: This study …
福辛普利联合通心络胶囊对心衰患者心功能及IL-17, CRP 水平的影响.
石俊宏， 刘琳妍， 罗裕， 王亮… - Progress in Modern …, 2017 - search.ebscohost.com
摘要目的: 探讨福辛普利联合通心络胶囊对心衰患者心功能及IL-17, CRP 水平的影响. 方法: 108
例心力衰竭患者(CHF) 依据随机数字表法分为两组: 对照组采用福辛普利治疗 …
例心力衰竭患者(CHF) 依据随机数字表法分为两组: 对照组采用福辛普利治疗 …
不同剂量阿托伐他汀对冠脉介入术后血脂, 脂联素和炎性因子的影响研究
曲伟峰 - 社区医学杂志, 2015 - cqvip.com
目的探讨不同剂量的阿托伐他汀对冠脉介入术后患者血脂, 脂联素和炎性因子的影响.
方法选择2006 年2 月—2013 年8 月收治的行PCI 的急性冠脉综合症患者120 例作为研究对象 …
方法选择2006 年2 月—2013 年8 月收治的行PCI 的急性冠脉综合症患者120 例作为研究对象 …
辛伐他汀和阿托伐他汀钙降脂方案在心绞痛患者治疗中的应用价值比较
周琼 - 中国医药指南, 2015 - cqvip.com
目的研究辛伐他汀和阿托伐他汀钙降脂方案在心绞痛患者治疗中的应用价值. 方法将我院收治的
心绞痛患者纳入研究, 根据降脂方案不同分为辛伐他汀治疗的观察组和阿托伐他汀钙的对照组 …
心绞痛患者纳入研究, 根据降脂方案不同分为辛伐他汀治疗的观察组和阿托伐他汀钙的对照组 …
Urinary Biomarkers and Patient Outcome in Chronic Kidney Disease and Atherosclerotic Heart Disease: The value of IgM-uria and IgG-uria
R Tofik - 2014 - portal.research.lu.se
Risk stratification of patients with chronic kidney disease and atherosclerotic heart disease is
crucial. Microalbuminuria (MA) is associated with an increased risk of kidney and …
crucial. Microalbuminuria (MA) is associated with an increased risk of kidney and …